GE announced yesterday that it has completed an expansion project for
its healthcare manufacturing facility in Shanghai.
The second phase of
the project, located at Shanghai Zhangjiang High-tech Park, with a total
investment of 74 million US dollars, will double the capacity of the plant that
produces X Ray and MRI contrast agents as well as sterile injectable products
and nutritional supplements.
GE Healthcare Shanghai is the first US FDA
approved site for contrast agents in China. As one of the largest contrast agent
manufacturers in China, the company racked up domestic sales of about 26 million
US dollars in 2006 and exported production worth more than 95 million US
dollars. "The expansion project will make our Shanghai facility one of the
critical centers in the global supply chain for contrast agents and other
bioscience products," says Qian Weijia, General Manager of GE Healthcare
Shanghai.
GE, the world's largest multi-business company with products
and services ranging from aircraft engines, locomotives, power generation, oil
& gas, healthcare, lighting, water and security, to media and financial
services, has been actively expanding its presence in Shanghai in recent years
and its total investment in Shanghai now exceeds 554 million US dollars.
"The Shanghai government's plan to create a Better City, Better Life fits
well with GE's 'ecomagination' initiative that focuses on environmentally
friendly products," said Steve Bertamini, Chairman & CEO of GE North East Asia and Greater China.
"We are
confident that our strategic partnership with Shanghai will continue to
flourish," he said.
(For more biz stories, please visit Industry Updates)